BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 26457758)

  • 1. Excess TGF-β mediates muscle weakness associated with bone metastases in mice.
    Waning DL; Mohammad KS; Reiken S; Xie W; Andersson DC; John S; Chiechi A; Wright LE; Umanskaya A; Niewolna M; Trivedi T; Charkhzarrin S; Khatiwada P; Wronska A; Haynes A; Benassi MS; Witzmann FA; Zhen G; Wang X; Cao X; Roodman GD; Marks AR; Guise TA
    Nat Med; 2015 Nov; 21(11):1262-1271. PubMed ID: 26457758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A TGF-β pathway associated with cancer cachexia.
    Guttridge DC
    Nat Med; 2015 Nov; 21(11):1248-9. PubMed ID: 26540384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling.
    Regan JN; Waning DL; Guise TA
    Semin Cell Dev Biol; 2016 Jan; 49():24-9. PubMed ID: 26593325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle weakness in Ryr1I4895T/WT knock-in mice as a result of reduced ryanodine receptor Ca2+ ion permeation and release from the sarcoplasmic reticulum.
    Loy RE; Orynbayev M; Xu L; Andronache Z; Apostol S; Zvaritch E; MacLennan DH; Meissner G; Melzer W; Dirksen RT
    J Gen Physiol; 2011 Jan; 137(1):43-57. PubMed ID: 21149547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging.
    Andersson DC; Betzenhauser MJ; Reiken S; Meli AC; Umanskaya A; Xie W; Shiomi T; Zalk R; Lacampagne A; Marks AR
    Cell Metab; 2011 Aug; 14(2):196-207. PubMed ID: 21803290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal Cord Injury Leads to Hyperoxidation and Nitrosylation of Skeletal Muscle Ryanodine Receptor-1 Associated with Upregulation of Nicotinamide Adenine Dinucleotide Phosphate Oxidase 4.
    Liu XH; Harlow L; Graham ZA; Bauman WA; Cardozo C
    J Neurotrauma; 2017 Jun; 34(12):2069-2074. PubMed ID: 27998200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid hormone-related protein and bone metastases.
    Guise TA
    Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer.
    Johnson RW; Merkel AR; Page JM; Ruppender NS; Guelcher SA; Sterling JA
    Clin Exp Metastasis; 2014 Dec; 31(8):945-59. PubMed ID: 25359619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
    Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
    Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triadin binding to the C-terminal luminal loop of the ryanodine receptor is important for skeletal muscle excitation contraction coupling.
    Goonasekera SA; Beard NA; Groom L; Kimura T; Lyfenko AD; Rosenfeld A; Marty I; Dulhunty AF; Dirksen RT
    J Gen Physiol; 2007 Oct; 130(4):365-78. PubMed ID: 17846166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
    Yin JJ; Selander K; Chirgwin JM; Dallas M; Grubbs BG; Wieser R; Massagué J; Mundy GR; Guise TA
    J Clin Invest; 1999 Jan; 103(2):197-206. PubMed ID: 9916131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.
    Mourskaia AA; Dong Z; Ng S; Banville M; Zwaagstra JC; O'Connor-McCourt MD; Siegel PM
    Oncogene; 2009 Feb; 28(7):1005-15. PubMed ID: 19079339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca2+ release channel by NADPH oxidase 4.
    Sun QA; Hess DT; Nogueira L; Yong S; Bowles DE; Eu J; Laurita KR; Meissner G; Stamler JS
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):16098-103. PubMed ID: 21896730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RyR1-related myopathy mutations in ATP and calcium binding sites impair channel regulation.
    Yuan Q; Dridi H; Clarke OB; Reiken S; Melville Z; Wronska A; Kushnir A; Zalk R; Sittenfeld L; Marks AR
    Acta Neuropathol Commun; 2021 Nov; 9(1):186. PubMed ID: 34809703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitrosative modifications of the Ca2+ release complex and actin underlie arthritis-induced muscle weakness.
    Yamada T; Fedotovskaya O; Cheng AJ; Cornachione AS; Minozzo FC; Aulin C; Fridén C; Turesson C; Andersson DC; Glenmark B; Lundberg IE; Rassier DE; Westerblad H; Lanner JT
    Ann Rheum Dis; 2015 Oct; 74(10):1907-14. PubMed ID: 24854355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of TGFβ in Bone-Muscle Crosstalk.
    Regan JN; Trivedi T; Guise TA; Waning DL
    Curr Osteoporos Rep; 2017 Feb; 15(1):18-23. PubMed ID: 28161871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cAMP-response-element-binding protein positively regulates breast cancer metastasis and subsequent bone destruction.
    Son J; Lee JH; Kim HN; Ha H; Lee ZH
    Biochem Biophys Res Commun; 2010 Jul; 398(2):309-14. PubMed ID: 20599715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin β3 and TGF-β receptor type II.
    Page JM; Merkel AR; Ruppender NS; Guo R; Dadwal UC; Cannonier S; Basu S; Guelcher SA; Sterling JA
    Biomaterials; 2015 Sep; 64():33-44. PubMed ID: 26115412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model.
    Regan JN; Mikesell C; Reiken S; Xu H; Marks AR; Mohammad KS; Guise TA; Waning DL
    Front Endocrinol (Lausanne); 2017; 8():358. PubMed ID: 29312148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
    Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.